Oncology care in the era of pandemics.
Authors: Majeed H PMID: 32489247 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report.
Conclusions: This report describes the results of the first national survey assessing the impact of the covid-19 on Canadian medical oncologists and how they deliver systemic anticancer therapies. We hope that these data will provide a framework to address the challenges identified. PMID: 32489248 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
Conclusions: In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments. PMID: 32489249 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Epidemiology of adult and pediatric Burkitt lymphoma in Canada: sequelae of the HIV epidemic.
Conclusions: Current results highlight the geographic and historic pattern of bl in Canada. The human immunodeficiency virus remains an important risk factor for adult bl. PMID: 32489250 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.
Conclusions: Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer. PMID: 32489251 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

The most important attribute: stakeholder perspectives on what matters most in a physician.
Conclusions: All stakeholder group identified attributes in the Caring domain as being most important. Although all canmeds roles are important, our research highlights the priorities of stakeholders. PMID: 32489252 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients.
Authors: Dilalla V, Chaput G, Williams T, Sultanem K Abstract The Canadian Cancer Society estimated that 220,400 new cases of cancer would be diagnosed in 2019. Of the affected patients, more than 60% will survive for 5 years or longer after their cancer diagnosis. Furthermore, nearly 40% will receive at least 1 course of radiotherapy (rt). Radiotherapy is used with both curative and palliative intent: to treat early-stage or locally advanced tumours (curative) and for symptom management in advanced disease (palliative). It can be delivered systemically (external-beam rt) or internally (brachytherapy). Although tec...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Update on the subcutaneous administration of rituximab in Canadian cancer centres.
Authors: Stewart D, Aucoin JS, Crosbie T, Forman M, Lye E, Christofides A, Mitha A Abstract Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route, commonly because of shorter chair time and reduced risk of infusion-related reactions. Recent Canadian data, including those from the scuba study reported here, support the results of earlier international studies showing a reduction in preparation and administration time with the sc formulation, lower cost of adminis...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.
Conclusions: Nivolumab is an immunotherapy treatment that has proved to be an effective and well-tolerated therapeutic option in elderly patients with metastatic melanoma. PMID: 32489255 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Conclusions: Overall efficacy was similar in our patients receiving CyBorD and Bor-Dex. After ahsct, no difference in depth of response or pfs was observed. Cyclophosphamide-gcsf seems to increase collection failures and hospitalizations in patients receiving CyBorD. Prospective studies are required to examine that relationship. PMID: 32489256 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Impact of Recurrence Score on type and duration of chemotherapy in breast cancer.
Conclusions: In the present study, the availability of Oncotype dx testing was observed to influence the choice of chemotherapy type in the setting of early-stage bca. PMID: 32489257 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Digital gene expression analysis might aid in the diagnosis of thyroid cancer.
Conclusions: This preliminary proof-of-concept study suggests a role for nCounter technology, a digital gene expression analysis technique, as an adjunct assay for the molecular diagnosis of thyroid neoplasms. PMID: 32489258 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

How is best supportive care provided in clinical trials for patients with advanced cancer? A review of registered protocols of clinical trials.
We describe the characteristics of the trials, together with the definition and components of bsc. We analyzed how the trials met the standards and adopted the key components of bsc. Results: Of 193 trials retrieved, only 64 met the inclusion criteria; 36 of those trials (56%) had no definition of bsc. Less than 7% of the trials included even 3 of the 8 bsc standards that were defined to be included in the design of trials. Furthermore, trials mentioned only 5 of the 15 key components that the consensus defined to be fundamental, with symptom management appearing in 22% of trials and the other 4 components appearing in...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.
Conclusions: There is no evidence for or against the use of local or regional interventions other than transarterial chemoembolization for the treatment of intermediate- or advanced-stage hcc. Furthermore, there is no evidence to support the addition of sorafenib to any local or regional therapy. Sorafenib or lenvatinib are recommended for first-line systemic treatment of intermediate-stage hcc. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. Antiviral treatment is recommended in individuals with advanced hcc who are positive for the hepatitis B surface antigen. PMID: 32489260...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Organizational guidance for the care of patients with head-and-neck cancer in Ontario.
Conclusions: The recommendations contained in this document offer guidance for clinicians and institutions providing care for patients with head-and-neck cancer in Ontario, and for policymakers and other stakeholders involved in the delivery of health care services for head-and-neck cancer. PMID: 32489261 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer.
Authors: Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, Lau J, Thain L, Eisen A Abstract Background: In Ontario, there is no clearly defined standard of care for staging for distant metastasis in women with newly diagnosed and biopsy-confirmed breast cancer whose clinical presentation is suggestive of early-stage disease. This guideline addresses baseline imaging investigations for women with newly diagnosed primary breast cancer who are otherwise asymptomatic for distant metastasis. Methods: The medline and embase databases were systematically searched for evidence from January 2000 to April 2019, and t...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
Conclusions: This Canadian expert consensus statement and algorithm were driven by significant advances in the treatment of EGFR-mutated nsclc. PMID: 32489263 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.
Conclusions: The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer. PMID: 32489264 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Translating guidelines to practice: a training session about cancer-related fatigue.
Conclusions: The provided training is both acceptable to hcps and csps and feasible. It could increase knowledge of the capo crf guidelines and participant intentions and self-efficacy to implement evidence-based recommendations. Future studies should investigate actual changes in practice and how to optimize follow-up assessments. To promote practice uptake, kt strategies should be paired with guideline development. PMID: 32489265 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

HPV sampling options for cervical cancer screening: preferences of urban-dwelling Canadians in a changing paradigm.
Conclusions: The results demonstrate a strong preference for self-sampling among never-screened and not-recently-screened women, and provides initial evidence for policymakers and researchers to address how best to integrate self-sampling hpv screening into both organized and opportunistic screening contexts. PMID: 32489266 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.
Conclusions: In Ontario, the detection rate of CDH1 pvs in patients with dgc was low: no pvs were identified in patients with isolated dgc at less than 40 years of age, and 1 was identified in a patient with isolated dgc at less than 50 years of age. Isolated lbc with no dgc was observed in CDH1-positive families, as were pathology-confirmed nondgc or non-lbc malignancies, which had not previously been reported. Given a phenotype that overlaps with other hereditary conditions, multi-gene panels are recommended for all patients with dgc at less than 50 years of age and for those meeting igclc criteria. PMID: 32489267 [P...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.
Conclusions: In the present study, the most recent and largest administrative database analysis of a Canadian population to date, we observed a subtype distribution consistent with previously reported data, together with comparable annual incidence and overall survival patterns. PMID: 32489268 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Health care provider preferences for, and barriers to, cannabis use in cancer care.
Conclusions: The survey indicated that this group of oncology hcps believed that they lacked sufficient knowledge about cannabis to make recommendations to patients. In addition to that lack of knowledge, a number of notable barriers were reported, and more than half the hcps indicated interest in learning more about cannabis in the future. PMID: 32489269 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Health-related quality of life and well-being in parents of infants and toddlers with cancer.
Authors: Morhun JM, Racine NM, Guilcher GMT, Tomfohr-Madsen LM, Schulte FSM Abstract Background: The unique psychosocial needs of parents and caregivers of young children with cancer are poorly understood. The aims of the present study were to examine health-related quality of life (hrqol), stress, and psychological distress in parents of young children (0-4 years) diagnosed with cancer; and the associations between parent psychosocial functioning and child treatment characteristics. Methods: Parents (n = 35) with a child (n = 19 male, 54.3%) 0-48 months of age (median: 31.06 months) on active cancer therapy we...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Association between waiting time for radiotherapy after surgery for early-stage breast cancer and survival outcomes in Ontario: a population-based outcomes study.
Conclusions: Delay to the initiation of adjuvant rt after breast-conserving surgery is associated with inferior bca survival outcomes. The good prognosis for patients with early-stage bca limits the statistical power to detect an effect of delay to rt. Given that there is no plausible advantage to delay, we agree with Mackillop that time to initiation of rt should be kept "as short as reasonably achievable." PMID: 32489271 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Authors: Surinach A, Phung T, Abdul-Rahim O, Khushman M Abstract At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma (pdac) is the lowest of any cancer. The currently approved treatment options for metastatic pdac in the United States are folfirinox [irinotecan-fluorouracil (5fu)-leucovorin (lv)-oxaliplatin], gemcitabine-nab-paclitaxel, and liposomal irinotecan plus 5fu-lv. Liposomal irinotecan is a novel formulation of irinotecan encapsulated within a lipid bilayer, which favours local metabolic activation. The napoli-1 trial demonstrated the effic...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

The Canadian Cancer Research Conference 2019.
Authors: Galpin KJC, Cook DP, Salemi LM, Urowitz S, Williams C, Bell JC, Brundage MD, Vanderhyden BC Abstract The 5th Canadian Cancer Research Conference (ccrc) took place 3-5 November 2019 in Ottawa, Ontario. Nearly 1000 participants-scientists, oncologists, community members, and patients-gathered to share knowledge, foster collaboration, and fuel the future of cancer research in Canada. The scientific program included 3 plenary sessions, 26 concurrent sessions, and 2 poster sessions presenting research described in more than 600 submitted abstracts, giving participants the opportunity to share health research th...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-na ïve chronic lymphocytic leukemia.
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. Curr Oncol. 2020 Apr;27(2):e231-e245 Authors: Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P Abstract The 2019 annual meeting of the American Society of Hematology took place 7-10 December in Orlando, Florida. At the meeting, results from key studies in treatment-naïve chronic lymphocytic leukemia (cll) were presented. Of those studies, phase iii oral presentations focused on the efficacy and safety of therapy with inhibitors of Bruton ...
Source: Current Oncology - June 4, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

A new hope.
Authors: Wong R PMID: 32368172 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
This article reviews specific iraes by organ system, consolidating recommendations from multiple guidelines and incorporating data from case reports to highlight additional evolving therapeutic options for patients. Managing iraes requires early recognition, early intervention, and education of the patients and the multidisciplinary health care team alike. Given the durable responses observed with icit, and the irreversible nature of some of the iraes, further research into management of the sequelae of icit is required. PMID: 32368173 [PubMed - in process] (Source: Current Oncology)
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Use of immuno-oncology in melanoma.
Authors: Smylie MG Abstract Treatment options for patients with metastatic melanoma have expanded rapidly since the approval of ipilimumab by the U.S. Food and Drug Administration in 2011. Cytokines such as interferon and interleukin-2 were approved in 1995 and 1998 respectively. However, the effect on survival was marginal, and the toxicity, substantial. Multiple vaccine studies likewise failed to show improvements in survival. The "Holy Grail" came with the discovery of immune checkpoints, and the first metastatic melanoma trial to show an improvement in overall survival involved the use of an immune ch...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.
Authors: Mendis S, Gill S Abstract Immunotherapy has been described as the "fourth pillar" of oncology treatment, in conjunction with surgery, chemotherapy, and radiotherapy. However, the role of immunotherapy in gastrointestinal tumours is still evolving. Data for checkpoint inhibition in esophagogastric, hepatocellular, colorectal, and anal squamous cell carcinomas are expanding. In phase iii trials in the second-line setting, PD-1 inhibitors have demonstrated positive results for the subset of esophageal cancers that are positive for PD-L1 at a combined positive score of 10 or more. Based on results of...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Immune checkpoint inhibitors in genitourinary malignancies.
Authors: Thana M, Wood L Abstract Although immune-mediated therapies have been used in genitourinary (gu) malignancies for decades, recent advances with monoclonal antibody checkpoint inhibitors (cpis) have led to a number of promising treatment options. In renal cell carcinoma (rcc), cpis have been shown to have benefit over conventional therapies in a number of settings, and they are the standard of care for many patients with metastatic disease. Based on recent data, combinations of cpis and antiangiogenic therapies are likely to become a new standard approach in rcc. In urothelial carcinoma, cpis have been show...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Immuno-oncology-the new paradigm of lung cancer treatment.
Authors: Dawe DE, Harlos CH, Juergens RA Abstract Systemic therapy is an essential part of treatment for all patients with small-cell lung cancer (sclc) and for most patients with non-small-cell lung cancer (nsclc). Standards of care have evolved dramatically since 2009, especially in the setting of incurable or advanced nsclc. Part of that evolution has been the incorporation of immuno-oncology drugs, especially immune checkpoint inhibitors (icis) into multiple therapeutic scenarios. In the present review, we discuss the role of the immune system in lung cancer and the previous failures of immunotherapy for patien...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

A review of cancer immunotherapy: from the past, to the present, to the future.
Authors: Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Abstract Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Immunotherapy has now firmly established itself as a novel pillar of cancer care, from the metastatic stage to the adjuvant and neoadjuvant settings in numerous cancer types. In this review article, we highlight how the history of cancer immunotherapy paved the way for discoveries that are now part of the standard of care. W...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Targeting T cell activation in immuno-oncology.
Authors: Saibil SD, Ohashi PS Abstract The years since 2009 have seen tremendous progress in unlocking the curative potential of the immune system for the treatment of cancer. Much of that revolution in immuno-oncology has been fueled by the clinical success of immune checkpoint inhibitors, particularly those targeting the PD-1 axis. Unfortunately, many patients still fail to benefit from checkpoint blockade or other immunotherapies. An inability to fully activate antitumour T cells contributes in part to the failure of those therapies. Here, we review the basic biology of T cell activation, with particular emphasi...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Authors: Meyers DE, Banerji S Abstract Immune checkpoint inhibitor-based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell-mediated immune response, and immune modulation of the microenvironment that can help to predict i...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Chimeric antigen receptor T cell therapy comes to clinical practice.
Authors: Wall DA, Krueger J Abstract Adoptive cellular therapy with chimeric antigen receptor T cells (car-ts) has recently received approval from Health Canada and the U.S. Food and Drug Administration after remarkable and durable remissions were seen in children with recurrent or refractory leukemia and adults with non-Hodgkin lymphoma-responses that were so impressive that a shift in the paradigm of care has now occurred for children with acute lymphoblastic leukemia. The concept behind car-t immunotherapy is that modification of a patient's own T cells to facilitate their localization to the cancer cell, with s...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Immunotherapy in hematologic malignancies.
Authors: Kansara RR, Speziali C Abstract The management of hematologic malignancies has traditionally relied on chemotherapy regimens, many of which are still in use today. However, with advancements in the knowledge of tumour pathophysiology, therapies are continually evolving. Monoclonal antibodies against specific targets on tumour cells are now widely used to treat hematologic malignancies, either in combination with chemotherapy or as single agents. Rituximab, a monoclonal antibody against the CD20 antigen, is a good example of successful monoclonal antibody therapy that has improved outcomes for patients with...
Source: Current Oncology - May 7, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Oncologists and general practitioners in oncology: allies in cancer care delivery.
Authors: Chaput G, Lilly E PMID: 32218653 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

The evolving field of bone imaging in multiple myeloma: is it time to abandon skeletal surveys?
Authors: Mian HS, McCurdy A PMID: 32218654 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Does free nicotine replacement improve smoking cessation rates in cancer patients?
Authors: Arifin AJ, McCracken LC, Nesbitt S, Warner A, Dinniwell RE, Palma DA, Louie AV Abstract Background: Cigarette smoking is carcinogenic and has been linked to inferior treatment outcomes and complication rates in cancer patients. Here, we report the results of an 18-month pilot smoking cessation program that provided free nicotine replacement therapy (nrt). Methods: In January 2017, the smoking cessation program at our institution began offering free nrt for actively cigarette-smoking patients with cancer. The cost of 4 weeks of nrt was covered by the program, and follow-up was provided by smoking cessat...
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Acceptability of anal cancer screening tests for women living with HIV in the EVVA study.
Conclusions: Most participating women considered anal cancer screening necessary and very acceptable. Longer screening intervals and adequate pain management could further increase the acceptability of repeated screening. PMID: 32218656 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience.
Conclusions: In the Canadian setting, the acceptance of rebiopsy on progression was high. Multiple rebiopsies were clinically feasible and could increase the yield for T790M mutation. The incidence of complications was low despite the most common site for rebiopsy being lung. PMID: 32218657 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Analyzing the effect of physician assignment in the survival of patients with advanced non-small-cell lung cancer.
Conclusions: Practice size and proportion of patients treated varied between oncologists, but those differences did not translate into significantly different survival outcomes for patients. PMID: 32218658 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Prognosis in young women less than 40 years of age with brain metastasis from breast cancer.
Authors: Mustillo A, Ayoub JP, Charpentier D, Yelle L, Florescu M Abstract Background: Brain metastasis from breast cancer (bca) in young women is doubly devastating because both quality of life and life expectancy are significantly reduced. With new radiation technology and drugs that have emerged, survival is expected to increase for these young women. Methods: Using the oacis and sardo patient databases, we identified 121 patients diagnosed with bca and brain metastasis between 2006 and 2016 at the University of Montreal Hospital Centre. Those patients were divided into Group A, patients who developed brain ...
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Humanism in global oncology curricula: an emerging priority.
Conclusions: The proportion of humanistic competencies has been increasing in global oncology curricula over time, but the overall proportion remains low and represents a largely Western perspective on what constitutes humanism in health care. The representation of humanism focuses primarily on the iecares attributes of Respect, Compassion, and Empathy. PMID: 32218660 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020.
Authors: Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B Abstract Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Nevertheless, recent advances in the fields of immuno-oncology and precision medicine have led to significant improvements in clinical outcome in metastatic non-small-cell lung cancer (nsclc). Those improvements were facilitated by a greater understanding of the biologic classification of nsclc, which catalyzed discoveries of novel therapies. Here, we present a comprehensive review of the recent avalanche of practice-changing trials in ...
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study.
Conclusions: Most cases of pcc continue to be diagnosed at a late stage, with poor short-term and long-term prognoses. After adjustment for patient age, sex, and year of diagnosis, the survival for stage i tumours and for surgical modalities increased over time. Further research is needed to identify the reasons for improvement in survival during the study period. PMID: 32218662 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Patient and physician perceptions of lung cancer care in a multidisciplinary clinic model.
Conclusions: This qualitative study found that a lc mdc facilitated patient communication and physician collaboration, improved quality of care, and had a perceived positive effect on patient outcomes. PMID: 32218663 [PubMed - as supplied by publisher] (Source: Current Oncology)
Source: Current Oncology - March 29, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research